Effect of Botulinum Toxin Type A on Functional Mobility in Cerebral Palsy with Lower Limb Spasticity

Journal Title: Journal of Clinical and Diagnostic Research - Year 2018, Vol 12, Issue 5

Abstract

ABSTRACT Introduction: Children with Cerebral Palsy (CP) often start walking much later than typically developing children and they do so with a slower speed and higher energy cost. Mobility varies across different environmental settings and Functional Mobility Scale (FMS) was devised to illustrate functional mobility in these children over three distinct distances, chosen to represent mobility in the home, at school and in the wider community. Botulinum toxin A injections into the gastrocnemius muscle for equinus foot deformity, as well as multilevel lower limb injections have shown improvements in gait, however, there is paucity of literature on its effect on functional mobility. Aim: To study the efficacy of Botulinum toxin A injection in CP with lower limb spasticity in terms of reduction in spasticity and effect on functional mobility. Materials and Methods: A total of 31 children were enrolled and evaluated for various outcome measures just before injection and at 4 and 12 weeks after injection. Change in FMS on follow-up was analysed using Wilcoxon signed-rank test. Spearman’s correlation analysis was performed between the number of injected muscles in each child and change in FMS scores on follow-up. A p-value of <0.05 was considered statistically significant. Analyses were done using SPSS version 21.0 statistical software (IBM Corp., Armonk, NY). Results: At distances of 5, 50 and 500 meters, FMS showed statistically significant improvement at four weeks (p-value <0.001 at 5; 0.002 at 50; 0.006 at 500 meters) and at 12 weeks (p-value <0.001 at 5; 0.001 at 50; 0.002 at 500 meters) compared with baseline but no significant change from 4 to 12 weeks (p-value=0.102 at 5; 1.000 at 50; 0.157 at 500 meters). There was moderate positive correlation between the number of injected muscles in each child and the change in FMS from baseline to 12 weeks at 5 meters distance; however, a moderate negative correlation was observed for the same at 500 meters. Conclusion: Local injection of Botulinum toxin A is effective in reducing the lower limb (gastrocnemius, hamstring, adductor) spasticity in CP children. It also improves the FMS in CP children.

Authors and Affiliations

Abhimanyu Vasudeva, Nonica Laisram, Asem Rangita Chanu

Keywords

Related Articles

Molecular Characterisation of Stenotrophomonas maltophilia in Nosocomial Infections: Challenges and Way Forward

ABSTRACT Introduction: Stenotrophomonas maltophilia (S. maltophilia), is an important rapidly emerging, opportunistic, non-fermenting Gram negative bacillus with high intrinsic resistance to drugs. It is one of the leadi...

Isoniazid Induced Toxic Epidermal Necrolysis in a HIV Positive Patient during Treatment for Extra Pulmonary Tuberculosis: A Case Report

ABSTRACT Toxic Epidermal Necrolysis (TEN) is characterised by extensive erythema, necrosis, and bullous detachment of the epidermis and mucous membranes. Drug induced TEN is commonly seen with sulphonamides, penicillins,...

Correlation between Postnatal Weight Gain and Development of Retinopathy of Prematurity: An Experience in Rural Tertiary Care Centre

ABSTRACT Introduction: Retinopathy Of Prematurity (ROP) is one of the leading causes of preventable blindness in our country. The minor risk factors responsible for development of such at Neonatal Intensive Care Unit (NI...

Clinical and Investigative Study of Hirsutism

ABSTRACT Introduction: Hirsutism is the presence of excessive terminal hair in androgen-dependent areas in a female with varied aetiology. The most common endocrine disorder leading to hirsutism is Polycystic Ovary Syndr...

Download PDF file
  • EP ID EP524378
  • DOI 10.7860/JCDR/2018/34639.11554
  • Views 66
  • Downloads 0

How To Cite

Abhimanyu Vasudeva, Nonica Laisram, Asem Rangita Chanu (2018). Effect of Botulinum Toxin Type A on Functional Mobility in Cerebral Palsy with Lower Limb Spasticity. Journal of Clinical and Diagnostic Research, 12(5), 5-9. https://europub.co.uk/articles/-A-524378